Belgium · Delayed Price · Currency is EUR argenx SE Company Description
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.
In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,863 |
| CEO | Timothy Van Hauwermeiren |
Contact Details
Address: Laarderhoogtweg 25 Amsterdam, 1101 EB Netherlands | |
| Phone | 31 10 703 8441 |
| Website | argenx.com |
Stock Details
| Ticker Symbol | ARGX |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | NL0010832176 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Van Hauwermeiren EMBA, M.Sc. | Co-Founder, Chief Executive Officer and Executive Director |
| Karl Gubitz | Chief Financial Officer |
| Karen Massey | Chief Operating Officer |
| Dr. Peter Ulrichts | Chief Scientific Officer |
| Malini Moorthy | General Counsel and Corporate Secretary |
| Arjen Lemmen M.Sc. | Vice President of Corporate Development and Strategy |
| Andria Wilk | Global Head of Quality |
| Dr. Luc Truyen | Chief Medical Officer |
| Prof. Hans de Haard Ir, Ph.D. | Co-Founder and Member of Board Advisors |
| Filip Borgions | Chief Technology Innovation Officer |